Aelis Farma SA AI Stock Analysis
Want to see FR:AELIS full AI Analyst Report?
Aelis Farma SA (AELIS) AI Stock Analysis
Aelis Farma SA
(Paris:AELIS)
The score is primarily constrained by very weak financial performance, including persistent losses, equity erosion, and cash burn. Mixed technical momentum provides limited support, while the negative P/E further weakens the outlook. Earnings-call and corporate-event components were excluded because no usable data was provided.
Aelis Farma SA (AELIS) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 12.54M
- Dividend Yield
- ―
- Average Volume (3M)
- 20.71K
- Price to Earnings (P/E)
- -2.8
- Beta (1Y)
- 0.73
- Revenue Growth
- -97.09%
- EPS Growth
- 45.00%
- Country
- France
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Aelis Farma SA Business Overview & Revenue Model
Company Description
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-speci...
Aelis Farma SA Financial Statement Overview
Summary
Financial performance is materially weak: revenue contracted sharply, losses widened, equity eroded, and operating cash flow remained negative. The underlying average of the provided financial scores is below the permitted minimum, so the score is set to 37.
Income Statement
25NegativeBalance Sheet
45NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.64M | 2.08M | 2.68M | 9.05M | 3.81M | 9.07M |
| Gross Profit | -3.10M | -279.00K | 2.68M | 9.05M | 3.81M | 9.07M |
| EBITDA | -7.08M | -8.00M | -7.18M | -6.35M | -16.23M | 844.00K |
| Net Income | -4.52M | -6.43M | -7.46M | -5.08M | -14.29M | 574.00K |
Balance Sheet | ||||||
| Total Assets | 8.44M | 12.05M | 19.71M | 26.28M | 39.22M | 28.31M |
| Cash, Cash Equivalents and Short-Term Investments | 6.62M | 8.21M | 14.05M | 20.23M | 34.40M | 24.71M |
| Total Debt | 4.38M | 6.60M | 6.25M | 4.04M | 3.82M | 6.41M |
| Total Liabilities | 6.12M | 7.61M | 9.59M | 13.08M | 19.43M | 27.41M |
| Stockholders Equity | 2.31M | 4.44M | 10.12M | 13.20M | 19.79M | 899.00K |
Cash Flow | ||||||
| Free Cash Flow | -3.48M | -5.39M | -11.72M | -12.67M | -13.19M | 18.76M |
| Operating Cash Flow | -3.48M | -5.38M | -11.53M | -12.59M | -13.05M | 18.97M |
| Investing Cash Flow | -837.00K | -841.00K | -190.00K | -88.00K | -86.00K | -212.00K |
| Financing Cash Flow | -703.00K | 538.00K | 5.81M | -1.34M | 22.10M | 180.00K |
Aelis Farma SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AELIS, the sentiment is Positive. The current price of 0.92 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.84, and below the 200-day MA of 1.10, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 60.72 is Neutral, neither overbought nor oversold. The STOCH value of 41.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:AELIS.
Aelis Farma SA Peers Comparison
Overall Rating
FR:POXEL46Neutral
FR:AELIS43Neutral
FR:SIGHT43Neutral
FR:ALBPS42Neutral
FR:ALDVI39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | EUR 7.83M | -0.38 | 33.88% | ― | ― | ― | |
| 43Neutral | EUR 12.61M | -2.79 | ― | ― | -97.09% | 45.00% | |
| 43Neutral | EUR 18.44M | -1.03 | 52.39% | ― | -610.31% | 43.88% | |
| 42Neutral | EUR 14.54M | -0.02 | 153.48% | ― | ― | 90.97% | |
| 39Underperform | EUR 9.55M | 220.16 | -0.18% | ― | 0.10% | 99.69% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:AELIS | Aelis Farma SA | 0.92 | -0.17 | -15.60% | |
| FR:POXEL | Poxel SA | 0.14 | -0.12 | -44.87% | |
| FR:SIGHT | GenSight Biologics | 0.07 | -0.03 | -27.18% | |
| FR:ALDVI | Advicenne SA | 0.66 | -0.95 | -59.10% | |
| FR:ALBPS | Biophytis SA | 0.04 | -0.05 | -56.47% | |
| FR:ALNFL | NFL Biosciences SA | 0.35 | -0.54 | -60.34% |
Aelis Farma SA Corporate Events
Aelis Farma Reports Caregiver-Observed Benefits for AEF0217
Aelis Farma is a clinical-stage biopharmaceutical company developing CB1 receptor treatments for cognitive impairments and related conditions. Its lead candidate, AEF0217, is a first-in-class signaling-specific CB1 inhibitor with a development focus...
Aelis Farma Publishes 2026 Half-Year Financial Report
Aelis Farma announced that its 2026 half-year financial report has been filed with the French Financial Markets Authority and is now available to the public on the company’s website. The publication offers investors and stakeholders updated visibilit...
Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances
In the first half of 2026, Aelis Farma advanced its clinical priorities, most notably the international Phase 2b trial of AEF0217 in people with Down syndrome, with recruitment on track and a positive safety committee recommendation. A key regulatory...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
